Michael acceptors as cysteine protease inhibitors

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Cysteine proteases play crucial roles in biological processes but their dysregulation is linked to numerous diseases.
• Uncontrolled proteolysis by cysteine proteases contributes to conditions like cancer, inflammation, and neurodegenerative disorders.
• Developing effective cysteine protease inhibitors is vital for therapeutic intervention.

Purpose of the Study:

• To review recent advancements in cysteine protease inhibitors.
• To focus on Michael acceptors as a class of irreversible cysteine protease inhibitors.
• To present examples of inhibitors that have advanced to clinical trials.

Main Methods:

• Literature review of scientific reports on cysteine protease inhibitors.
• Analysis of Michael acceptors, including vinyl sulfones, alpha,beta-unsaturated carbonyl derivatives, and aza-peptides.
• Examination of the mechanism of irreversible inhibition via active site alkylation.

Main Results:

• Michael acceptors irreversibly inhibit cysteine proteases by alkylating the active site cysteine residue through conjugate addition.
• Vinyl sulfones, alpha,beta-unsaturated carbonyl derivatives, and aza-peptides are identified as key classes of Michael acceptor inhibitors.
• Several Michael acceptor-based inhibitors have progressed to clinical testing, demonstrating therapeutic potential.

Conclusions:

• Michael acceptors represent a significant and promising class of cysteine protease inhibitors.
• The irreversible inhibition mechanism offers a robust strategy for therapeutic development.
• Further research and clinical evaluation of these inhibitors are warranted for various disease states.